TOTAL VOLUME:

$134.2b

24H VOL:

$129,159,707

24H TRANSACTIONS:

2,388,728,490

OPEN INTEREST:

$1,442,132,418

404,744

Markets across

30,489

events

MATCHED EVENTS:

2,691

PLATFORM COVERAGE:

5

Polymarket:

39%

VS.

Kalshi:

61%

BETA
Dashboards
Insights
Indices
Tour
All
Trending
Breaking
New
Ending Soon
Politics
Sports
Crypto
Companies
Elections
Financials
Economics
Other
Entertainment
Science and Technology
FDA decision: Oveporexton by Takeda (in 2026)
kalshi

FDA decision: Oveporexton by Takeda (in 2026)

Volume:
$1,964

A full approval or an accelerated approval

 - Kalshi

A full approval or an accelerated approval - Kalshi

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Aug 6, 2026

Closed: Aug 5, 9:35 PM EST

kalshi

Kalshi

View
Join Kalshi and score $25 for your first trade.
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
kalshi

A full approval or an accelerated approval

View
100%
Yes 100¢No 0¢
100¢
N/A
$1,964
N/A
N/A
$1,665
3mo 3d
Yes
Total markets: 1

Description

This event tracks whether the FDA will grant approval to Takeda's drug Oveporexton by a specified deadline in 2026. The outcome depends on the FDA's regulatory decision, which could result in either full approval, accelerated approval, or rejection/other outcomes. Investors are betting on whether the pharmaceutical company will successfully meet regulatory requirements for this treatment.

Kalshi

If the FDA's decision on Oveporexton by Takeda in 2026 is A full approval or an accelerated approval, the market resolves to Yes.

Frequently asked questions

On Kalshi, this dashboard tracks the current odds and price history for the FDA Oveporexton approval market, along with 24-hour volume of $1,594. It provides a visual representation of how traders on Kalshi are pricing the likelihood of approval, updated in real time to reflect market activity and sentiment around this potential pharmaceutical outcome.

This market resolves around Jan 1, 2027, with the outcome confirmed once the event is verifiable from credible public reporting. A binary signal — approval or non-approval — will close all positions, reflecting the official FDA decision based on regulatory review milestones and announced results.

Several signals could shift this market before Jan 1, 2027. Key catalysts include regulatory updates, clinical trial results, management guidance from Takeda, and analyst reports. Any public statements about safety profiles, manufacturing capabilities, or competitor activity may also influence trader sentiment. Additionally, broader market conditions and investor risk appetite in the pharmaceutical sector can cause volatility, especially as the projected 2026 decision date approaches.